Management of nonalcoholic fatty liver disease in the Middle East

Faisal M Sanai 1, Faisal Abaalkhail 2, Fuad Hasan 3, Muhammad Hamed Farooqi 4, Nawal Al Nahdi 5, Zobair M Younossi 6

Affiliations

07 July 2020

-

doi: 10.3748/wjg.v26.i25.3528

Abstract

The prevalence of nonalcoholic fatty liver disease (NAFLD) in the Middle East is increasing in parallel to an increase in the prevalence of associated risk factors such as obesity, metabolic syndrome, and type 2 diabetes mellitus. About 20% to 30% of the patients progress to develop nonalcoholic steatohepatitis (NASH), a histological subtype of NAFLD, with features of hepatocyte injury such as hepatocyte ballooning. NASH can progress to fibrosis, cirrhosis, and even hepatocellular carcinoma. NAFLD thus causes a substantial burden on healthcare systems and it is imperative that appropriate strategies are discussed at a regional level to facilitate effective management tailored to the needs of the region. To fulfil this unmet need, expert gastroenterologists, hepatologists, and endocrinologists from the region came together in three advisory board meetings that were conducted in Saudi Arabia, United Arab Emirates, and Kuwait, to discuss current local challenges in NAFLD screening and diagnosis, and the different available management options. The experts discussed the disease burden of NAFLD/NASH in the Middle East; screening, diagnosis, and referral patterns in NAFLD; and available treatment options for NAFLD and NASH. This paper summarizes the discussions and opinion of the expert panel on the management of NAFLD/NASH and also presents an extensive literature review on the topic.

Keywords: Expert opinion; Middle East; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis.

Conflict of interest statement

Conflict-of-interest statement: None of the authors received any fees for writing this manuscript. Medical writing assistance was funded by Gilead Sciences. No other conflict is declared.

Cited by

Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients.

Kanaan R, Yaghi C, Saade Riachy C, Schlosser A, Hamade A, Holmskov U, Medlej-Hashim M, Sørensen GL, Jounblat R.JGH Open. 2023 Feb 23;7(3):197-203. doi: 10.1002/jgh3.12873. eCollection 2023 Mar.PMID: 36968563 Free PMC article.

The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019.

Chen H, Zhan Y, Zhang J, Cheng S, Zhou Y, Chen L, Zeng Z.JMIR Public Health Surveill. 2022 Dec 12;8(12):e34809. doi: 10.2196/34809.PMID: 36508249 Free PMC article.

Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease.

Yang B, Yang X, Tan X, Lu L, Fan W, Barbier-Torres L, Steggerda J, Liu T, Yang H.Can J Gastroenterol Hepatol. 2022 Nov 8;2022:6799414. doi: 10.1155/2022/6799414. eCollection 2022.PMID: 36397950 Free PMC article. Review.

Fluctuating hepatitis B viremia: Full of sound and fury, signifying nothing?

Nguyen HH, Lee SS.Saudi J Gastroenterol. 2022 Sep-Oct;28(5):319-321. doi: 10.4103/sjg.sjg_307_22.PMID: 35946260 Free PMC article. No abstract available.

Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.

Anstee QM, Hallsworth K, Lynch N, Hauvespre A, Mansour E, Kozma S, Marino JP, Bottomley J, Piercy J, Higgins V.JHEP Rep. 2021 Nov 22;4(1):100411. doi: 10.1016/j.jhepr.2021.100411. eCollection 2022 Jan.PMID: 34977520 Free PMC article.

References

  1.  
    1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357. - PubMed
  2.  
    1. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402. - PubMed
  3.  
    1. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–974. - PubMed
  4.  
    1. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550–556. - PubMed
  5.  
    1. Vuppalanchi R, Chalasani N. Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat. Dig Dis Sci. 2016;61:1790–1792. - PubMed
  6.  
    1. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20:205–214. - PubMed
  7.  
    1. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37 Suppl 1:81–84. - PubMed
  8.  
    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. - PubMed
  9.  
    1. Alswat K, Aljumah AA, Sanai FM, Abaalkhail F, Alghamdi M, Al Hamoudi WK, Al Khathlan A, Al Quraishi H, Al Rifai A, Al Zaabi M, Babatin MA, Estes C, Hashim A, Razavi H. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. Saudi J Gastroenterol. 2018;24:211–219. - PMC - PubMed
  10.  
    1. Younossi ZM, Yu ML, El Kassas M, Esmat G, Yilmaz Y, Fernandez MC, Duseja AK, Isakov VA, Buti M, Mendez‐Sanchez N, Papatheodoridis GV, Chan WK, George J, Bugianesi E, Romero‐Gomez M, Roberts SK, Younes Z, Wai‐Sun Wong V, Fan JG, Eguchi Y, Gordon SC, Ahmed A, Ong J, Jacobson IM, Rinella ME, Hamid SS, Ziayee M, Younossi I, Lam BP, Arrese M, Nader F, Racila A, Henry L, Stepanova M on behalf of the Global NASH Council. Clinical and Patient‐Reported Outcomes Data for Patients with Non‐Alcoholic Fatty Liver Disease (NAFLD) and Non‐Alcoholic Steatohepatitis (NASH) Across the World: Data from the Global NASH Registry. Hepatology. 2019;70(S1):i–ii, 1-1476. Available from: https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.30941. - DOI
  11.  
    1. Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol. 2017;23:6571–6592. - PMC - PubMed
  12.  
    1. Hajat C, Harrison O, Al Siksek Z. Weqaya: a population-wide cardiovascular screening program in Abu Dhabi, United Arab Emirates. Am J Public Health. 2012;102:909–914. - PMC - PubMed
  13.  
    1. Radwan H, Ballout RA, Hasan H, Lessan N, Karavetian M, Rizk R. The Epidemiology and Economic Burden of Obesity and Related Cardiometabolic Disorders in the United Arab Emirates: A Systematic Review and Qualitative Synthesis. J Obes. 2018;2018:2185942. - PMC - PubMed
  14.  
    1. Memish ZA, El Bcheraoui C, Tuffaha M, Robinson M, Daoud F, Jaber S, Mikhitarian S, Al Saeedi M, AlMazroa MA, Mokdad AH, Al Rabeeah AA. Obesity and associated factors--Kingdom of Saudi Arabia, 2013. Prev Chronic Dis. 2014;11:E174. - PMC - PubMed
  15.  
    1. Al-Quwaidhi AJ, Pearce MS, Critchley JA, Sobngwi E, O'Flaherty M. Trends and future projections of the prevalence of adult obesity in Saudi Arabia, 1992-2022. East Mediterr Health J. 2014;20:589–595. - PubMed
  16.  
    1. Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82–97. - PubMed
  17.  
    1. Alqahtani A, Elahmedi M, Alswat K, Arafah M, Fagih M, Lee J. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy. Surg Obes Relat Dis. 2017;13:1599–1609. - PubMed
  18.  
    1. International Diabetes Federation, Diabetes Atlas. Eighth Edition 2017. [accessed 2019 Nov 07]. In: idf.org [Internet] Available from: https://www.idf.org/our-network/regions-members/middle-east-and-north-af....
  19.  
    1. Alzaid A. Diabetes: A tale of two cultures. 2012;12:57–59.
  20.  
    1. Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, Lai Z. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. Medicine (Baltimore) 2017;96:e8179. - PMC - PubMed
  21.  
    1. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71:793–801. - PubMed
  22.  
    1. Amiri Dash Atan N, Koushki M, Motedayen M, Dousti M, Sayehmiri F, Vafaee R, Norouzinia M, Gholami R. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2017;10:S1–S7. - PMC - PubMed
  23.  
    1. Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. Diabetes Care. 2018;41:372–382. - PubMed
  24.  
    1. Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015;38:1347–1355. - PMC - PubMed
  25.  
    1. Ansarimoghaddam A, Adineh HA, Zareban I, Iranpour S, HosseinZadeh A, Kh F. Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies. Diabetes Metab Syndr. 2018;12:195–201. - PubMed
  26.  
    1. Al-Rubeaan K, Bawazeer N, Al Farsi Y, Youssef AM, Al-Yahya AA, AlQumaidi H, Al-Malki BM, Naji KA, Al-Shehri K, Al Rumaih FI. Prevalence of metabolic syndrome in Saudi Arabia - a cross sectional study. BMC Endocr Disord. 2018;18:16. - PMC - PubMed
  27.  
    1. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923. - PubMed
  28.  
    1. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA NASH Clinical Research Network (CRN) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810–820. - PMC - PubMed
  29.  
    1. Babusik P, Bilal M, Duris I. Nonalcoholic fatty liver disease of two ethnic groups in Kuwait: comparison of prevalence and risk factors. Med Princ Pract. 2012;21:56–62. - PubMed
  30.  
    1. Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines (Basel) 2019:6. - PMC - PubMed
  31.  
    1. Tesfay M, Goldkamp WJ, Neuschwander-Tetri BA. NASH: The Emerging Most Common Form of Chronic Liver Disease. Mo Med. 2018;115:225–229. - PMC - PubMed
  32.  
    1. National Guideline Centre (UK) 2016
  33.  
    1. Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70–85. - PubMed
  34.  
    1. Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc. 2015;90:1233–1246. - PMC - PubMed
  35.  
    1. Tsai E, Lee TP. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2018;22:73–92. - PubMed
  36.  
    1. Younossi ZM, Stepanova M, Lawitz EJ, Reddy KR, Wai-Sun Wong V, Mangia A, Muir AJ, Jacobson I, Djedjos CS, Gaggar A, Myers RP, Younossi I, Nader F, Racila A. Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. Am J Gastroenterol. 2019;114:1636–1641. - PubMed
  37.  
    1. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45. - PMC - PubMed
  38.  
    1. Day J, Patel P, Parkes J, Rosenberg W. Derivation and Performance of Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the Detection and Prognosis of Liver Fibrosis. J Appl Lab Med. 2019;3:815–826. - PubMed
  39.  
    1. Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Aliment Pharmacol Ther. 2013;37:392–400. - PubMed
  40.  
    1. Demir M, Lang S, Nierhoff D, Drebber U, Hardt A, Wedemeyer I, Schulte S, Quasdorff M, Goeser T, Töx U, Steffen HM. Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease. J Clin Gastroenterol. 2013;47:719–726. - PubMed
  41.  
    1. Petta S, Vanni E, Bugianesi E, Di Marco V, Cammà C, Cabibi D, Mezzabotta L, Craxì A. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2015;35:1566–1573. - PubMed
  42.  
    1. Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017;9:715–732. - PMC - PubMed
  43.  
    1. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149:389–397.e10. - PMC - PubMed
  44.  
    1. Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265–1273. - PubMed
  45.  
    1. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Goodman Z. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–1882. - PubMed
  46.  
    1. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R, Loomba R. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65:1557–1565. - PMC - PubMed
  47.  
    1. Alexander M, Loomis AK, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Kendrick S, Waterworth DM, Sattar N, Alazawi W. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 2018;16:130. - PMC - PubMed
  48.  
    1. Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, Kontogianni MD. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017;68:119–132. - PubMed
  49.  
    1. Bradford V, Dillon J, Miller M. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease. Hepat Med. 2014;6:1–10. - PMC - PubMed
  50.  
    1. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885–904. - PubMed
  51.  
    1. Hannah WN, Jr, Harrison SA. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1365–1374. - PubMed
  52.  
    1. Glass LM, Dickson RC, Anderson JC, Suriawinata AA, Putra J, Berk BS, Toor A. Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60:1024–1030. - PubMed
  53.  
    1. Haukeland JW, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjøro K, Haaland T, Løberg EM, Birkeland K. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol. 2009;44:853–860. - PubMed
  54.  
    1. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroenterol. 2009;2:157–163. - PMC - PubMed
  55.  
    1. Nair S, Diehl AM, Wiseman M, Farr GH, Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;20:23–28. - PubMed
  56.  
    1. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–2307. - PubMed
  57.  
    1. Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, Webb A, Portillo-Sanchez P. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016;165:305–315. - PubMed
  58.  
    1. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176–1184. - PubMed
  59.  
    1. Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med. 2015;8:3924–3934. - PMC - PubMed
  60.  
    1. Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, Nakade Y, Ito K, Fukuzawa Y, Yoneda M. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015;31:923–930. - PubMed
  61.  
    1. Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46. - PubMed
  62.  
    1. Klein EA, Thompson IM, Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA. 2011;306:1549–1556. - PMC - PubMed
  63.  
    1. Abner EL, Schmitt FA, Mendiondo MS, Marcum JL, Kryscio RJ. Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci. 2011;4:158–170. - PMC - PubMed
  64.  
    1. Said A, Akhter A. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. Ann Hepatol. 2017;16:538–547. - PubMed
  65.  
    1. Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol. 2017;8:51–58. - PMC - PubMed
  66.  
    1. Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015;47:4–11. - PubMed
  67.  
    1. Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, Romon M, Duhamel A, Pattou F, Mathurin P. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology. 2015;149:379–88; quiz e15-6. - PubMed
  68.  
    1. Bower G, Toma T, Harling L, Jiao LR, Efthimiou E, Darzi A, Athanasiou T, Ashrafian H. Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology. Obes Surg. 2015;25:2280–2289. - PubMed
  69.  
    1. Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. Hepatology. 2017;65:1156–1164. - PubMed
  70.  
    1. Alnageeb H, Abdelgadir E, Khalifa A, Suliman M, Gautam SC, Layani L, Subramaniam S, Bashier A. Efficacy of bariatric surgery in improving metabolic outcomes in patients with diabetes. A 24-month follow-up study from a single center in the UAE. Diabetes Metab Syndr Obes. 2018;11:459–467. - PMC - PubMed
  71.  
    1. Aldoheyan T, Hassanain M, Al-Mulhim A, Al-Sabhan A, Al-Amro S, Bamehriz F, Al-Khalidi H. The effects of bariatric surgeries on nonalcoholic fatty liver disease. Surg Endosc. 2017;31:1142–1147. - PubMed
  72.  
    1. Alamri AA, Alsadiqi AI, Dahlawi A, Alghamdi A, Alnefaie M, Alhazmi M, Tewfik O, Almaymuni A, Al-Abbadi H, Mosli M. Are patients aware of potential risks of weight reduction surgery? An internet based survey. Saudi J Gastroenterol. 2019;25:97–100. - PMC - PubMed
  73.  
    1. Bzowej NH. Nonalcoholic steatohepatitis: the new frontier for liver transplantation. Curr Opin Organ Transplant. 2018;23:169–174. - PubMed
  74.  
    1. Al-Hamoudi W, Elsiesy H, Bendahmash A, Al-Masri N, Ali S, Allam N, Al Sofayan M, Al Bahili H, Al Sebayel M, Broering D, Saab S, Abaalkhail F. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. World J Gastroenterol. 2015;21:8140–8147. - PMC - PubMed
  75.  
    1. Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68:361–371. - PMC - PubMed
  76.  
    1. Connolly JJ, Ooka K, Lim JK. Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. J Clin Transl Hepatol. 2018;6:264–275. - PMC - PubMed
  77.  
    1. Al-Hussaini A, Bashir MS, Khormi M, AlTuraiki M, Alkhamis W, Alrajhi M, Halal T. Overweight and obesity among Saudi children and adolescents: Where do we stand today? Saudi J Gastroenterol. 2019;25:229–235. - PMC - PubMed
  78.  
    1. Lazarus JV, Ekstedt M, Marchesini G, Mullen J, Novak K, Pericàs JM, Roel E, Romero-Gómez M, Ratziu V, Tacke F, Cortez-Pinto H, Anstee QM EASL International Liver Foundation NAFLD Policy Review Collaborators. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. J Hepatol. 2020;72:14–24. - PubMed
  79.  
    1. Alsaif FA, Alqahtani SH, Alsadoon AM, Alswat KA, Abdo AA, Hassanain MM, Alsharabi AB, Aljuhani GR, Alkhalidi HM, Elsharkawy MS, Alotaibi MA, Sanai FM, Al-Hamoudi WK. Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease. Saudi J Gastroenterol. 2020 - PMC - PubMed
  80.  
    1. Alaama T. Nonalcoholic fatty liver disease: One more reason to strengthen public health. Saudi J Gastroenterol. 2018;24:199–200. - PMC - PubMed
  81.  
    1. Haroun D, Mechli R, Sahuri R, AlKhatib S, Obeid O, El Mallah C, Wood L, AlSuwaidi K. Metabolic syndrome among adolescents in Dubai, United Arab Emirates, is attributable to the high prevalence of low HDL levels: a cross-sectional study. BMC Public Health. 2018;18:1284. - PMC - PubMed
  82.  
    1. Al Zenki S, Al Omirah H, Al Hooti S, Al Hamad N, Jackson RT, Rao A, Al Jahmah N, Al Obaid I, Al Ghanim J, Al Somaie M, Zaghloul S, Al Othman A. High prevalence of metabolic syndrome among Kuwaiti adults--a wake-up call for public health intervention. Int J Environ Res Public Health. 2012;9:1984–1996. - PMC - PubMed
  83.  
    1. Weiderpass E, Botteri E, Longenecker JC, Alkandari A, Al-Wotayan R, Al Duwairi Q, Tuomilehto J. The Prevalence of Overweight and Obesity in an Adult Kuwaiti Population in 2014. Front Endocrinol (Lausanne) 2019;10:449. - PMC - PubMed
  84.  
    1. Awad AI, Alsaleh FM. 10-year risk estimation for type 2 diabetes mellitus and coronary heart disease in Kuwait: a cross-sectional population-based study. PLoS One. 2015;10:e0116742. - PMC - PubMed
  85.  
    1. Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197–211. - PMC - PubMed
  86.  
    1. Leung JC, Loong TC, Pang J, Wei JL, Wong VW. Invasive and non-invasive assessment of portal hypertension. Hepatol Int. 2018;12:44–55. - PubMed

Page Navigation